HSCT-CHESS to Enhance Hematopoietic Transplant Recovery
OBJECTIVES:
Primary
- To evaluate the ability of a Web-based Hematopoietic Stem Cell Transplantation (HSCT-)
Comprehensive Health Enhancement Support System (HSCT-CHESS) to mitigate the impact of
a child's HSCT on the health-related quality of life, family functioning, knowledge,
skills, and processes of care of the accompanying parent.
Secondary
- To explore the potential mechanisms of action of HSCT-CHESS in improving outcomes in
these parents, in terms of parental activation, social support and/or coping skills.
- To explore the impact of HSCT-CHESS on the health-related quality of life of the
pediatric HSCT patient, as reported by the parent and child.
OUTLINE: This is a multicenter study. Pediatric hematopoietic stem cell transplantation
(HSCT) recipients (ages 2 months-18 years) and accompanying parents are asked to complete a
baseline assessment battery by the start of transplant conditioning (the 'run-in' period).
If either member of the participating dyad fails to complete all study measures* during this
time period, the dyad is withdrawn from the study. The dyads are randomized into 1 of 2
intervention arms.
NOTE: *Measures will not be collected from pediatric patients under 5 years of age at
baseline or follow-up.
- Arm I: Each dyad receives institution-specific usual care for 6 months, which typically
includes psychosocial support for the HSCT recipient and individualized or group
education and support for the accompanying parent during the peri-transplant period.
They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-)
Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months.
Accompanying parents also may identify a companion to receive access to the HSCT-CHESS
Web site.
The HSCT-CHESS Web site provides ready access to accurate information and resources about
pediatric HSCT, practical tips, organizational tools, and other supportive services for use
during the transplant process. While the Web site is designed primarily for use by the
accompanying parent, it also includes some resources for child and adolescent HSCT
recipients that the parent may choose to share. In addition to collecting data for later
analysis, the Web site tracking system allows for further tailoring of information and
support for the user, principally by time post transplant.
- Arm II: Each dyad receives institution-specific usual care for 6 months as described in
arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant
Information Network (BMT InfoNet).
Each dyad completes quality-of-life assessment (Child Health Ratings Inventory
[CHRIs]-General and CHRIs-HSCT) at day 45, and at 3, 6, 9, and 12 months and CHRIS-General
at baseline. The accompanying parent provides demographic information at baseline and 6
months and completes Patient Health Questionnaire (PHQ-9) for depression screening at
baseline and 6 and 9 months. The accompanying parent also completes other measures for
family and individual coping, social support, process of care, and Internet use at baseline
and 6 and 9 months.
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care
Effect of the Hematopoietic Stem Cell Transplantation Comprehensive Health Enhancement Support System (HSCT-CHESS) on health-related quality of life of the accompanying parent at study entry, day 45 and 3, 6, 9, and 12 months
No
Susan K. Parsons, MD, MRP
Principal Investigator
Tufts Medical Center Cancer Center
United States: Institutional Review Board
CDR0000613668
NCT00782145
June 2008
June 2011
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
Medical College of Wisconsin Cancer Center | Milwaukee, Wisconsin 53226 |
City of Hope Comprehensive Cancer Center | Duarte, California 91010 |
Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio 45229-3039 |
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |